As a step forward in the development of SBI-457-based CXCR6 antagonists, this study explores CXCR6 antagonism as a potential strategy to block crosstalk with sorafenib and β-catenin pathways and to increase response and overcome resistance to sorafenib in hepatocellular carcinoma [6]. The gene discussed is CXCR6; the disease is hepatocellular carcinoma.